Login to Your Account



Lessons in Expectation Management

Miscommunication Matters: Vanda Falls Despite Success

By Trista Morrison


Monday, July 7, 2008
When Vanda Pharmaceuticals Inc. released Phase III data showing that insomnia drug tasimelteon (VEC-162) met its primary endpoint of improving short-term sleep onset, the company's stock popped in early trading only to fall more than 15 percent for the day. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription